New drug aims to shield patients from Chemo's harsh side effects
NCT ID NCT07473128
Summary
This study is testing whether a drug called trilaciclib can protect patients' bone marrow from damage during chemotherapy for a type of lung cancer. About 120 people with limited-stage small cell lung cancer will receive either trilaciclib or a placebo before their chemo. The main goal is to see if trilaciclib reduces severe drops in white blood cells, a common and dangerous side effect of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIMITED STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.